GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Long-Term Debt & Capital Lease Obligation
中文

AngioDynamics (AngioDynamics) Long-Term Debt & Capital Lease Obligation : $0.0 Mil (As of Feb. 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. AngioDynamics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.0 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. AngioDynamics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.0 Mil. AngioDynamics's Total Assets for the quarter that ended in Feb. 2024 was $324.8 Mil. AngioDynamics's LT-Debt-to-Total-Asset for the quarter that ended in Feb. 2024 was 0.00.

AngioDynamics's LT-Debt-to-Total-Asset declined from Feb. 2023 (0.09) to Feb. 2024 (0.00). It may suggest that AngioDynamics is progressively becoming less dependent on debt to grow their business.


AngioDynamics Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for AngioDynamics's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Long-Term Debt & Capital Lease Obligation Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.41 40.00 20.00 25.00 49.82

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.81 49.82 - - -

AngioDynamics Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


AngioDynamics  (NAS:ANGO) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AngioDynamics's LT-Debt-to-Total-Asset ratio for the quarter that ended in Feb. 2024 is calculated as:

LT-Debt-to-Total-Asset (Q: Feb. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2024 )/Total Assets (Q: Feb. 2024 )
=0/324.842
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


AngioDynamics Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Industry
Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421